BAFF-R expression is downregulated during remission and successively increases again during relapse [147], suggesting its critical role in B-ALL pathogenesis and placing BAFF-R as a crucial therapeutic target in B-ALL. The gene discussed is TNFRSF13C; the disease is precursor B-cell acute lymphoblastic leukemia.